SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

SELLAS Life Sciences Group, Inc. (SLS) Expects REGAL Trial Results This Month

SELLAS reported Q3 2026 net loss of $10.1M, versus $6.8M in Q3 2025, and cash of approximately $134.7M at September 30, 2026. It expects topline results from the Phase 3 REGAL trial this month.Material DetailsContext by AI AnalystThis is a late-stage clinical catalyst update alongside quarterly fin…

SLS
SquawkNews Desk

Related stories

Volkswagen Plans Up to 100,000 Job Cuts by 2030 Volkswagen plans to cut up to 100,000 jobs worldwide by 2030 as it restructures operations. The headline says four German plants are at risk. M impact | EQUITY | Nov 15, 2026, 03:31 AM UTC US Air Travel Disruptions to Persist Until Late Sunday, FAA Head Says The FAA head said disruptions to US air travel are expected to persist until late Sunday. The wire reports airlines are canceling flights. M impact | EQUITY | Nov 15, 2026, 02:42 AM UTC Air Travel Disruptions Expected to Persist Into Sunday, Officials Say Officials say thousands of flights are affected as air travel issues are expected to continue well into Sunday. M impact | EQUITY | Nov 14, 2026, 11:56 PM UTC SpaceX Starship Returns to Landing Pad After 22-Hour Orbital Voyage SpaceX’s Starship returned from a 22-hour voyage in orbit and was caught by mechanical arms at the Texas launch tower, a first for the spacecraft. M impact | EQUITY | Nov 14, 2026, 10:39 PM UTC SpaceX Starship Returns to Landing Pad From Orbit SpaceX’s Starship returned to its landing pad from orbit, completing a test of reusable rockets. M impact | EQUITY | Nov 14, 2026, 10:39 PM UTC Air Travel Disruptions to Persist Into Sunday, Officials Say Officials say thousands of flights have been affected, with air travel issues expected to persist well into Sunday. M impact | EQUITY | Nov 14, 2026, 09:39 PM UTC